Molbio Diagnostics: The financial results for the period ended September 30, 2026
Molbio Diagnostics (MOLBIO) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹16,174 crore.
What happened
Molbio Diagnostics (MOLBIO) filed a disclosure with the exchanges on 5 November 2026 at 05:31 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Molbio Diagnostics is a small-cap company, with a market value of about ₹16,174 crore.
The stock last traded at ₹1,403.5, against a 52-week range of ₹926.4–₹1,686.8 (16.8% below the high).
Before this filing the shares had moved −8.1% over the month. Average daily turnover over the last 20 sessions was about ₹180 crore.
Promoters held 41.29% at the end of Q2 FY27. Foreign institutions owned 1.51% and domestic institutions 16.37%.
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
After those filings, the stock gained 4.0% on average the next trading day and was up 22.1% on average after five days (2 filings with price data).
Market-wide, 10,790 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 8 Sept 2026 | Investor Presentation on the Unaudited Financial Results (Standalone… | +11.6% | +20.4% |
| 5 Sept 2026 | , the financial results for the period ended Jun 30, 2026. | −3.7% | +23.9% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- MOLBIO DIAGNOSTICS LTD Share Price
- MOLBIO Share Price Today - MOLBIO DIAGNOSTICS LTD Stock Price Live NSE/BSE
- Molbio Diagnostics IPO GMP Today, Expected Listing Gain & Price Band
- Molbio Diagnostics Limited reports Q2 and H1 FY27 financial results
- Molbio Diagnostics reports unaudited financial results for Q2 FY27
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.